Genor Biopharma Passes the Hearing for Hong Kong IPO
Genor Biopharma submitted the IPO application this June and passed the hearing from the Hong Kong Stock Exchange Committee. By far, the company has established several product pipelines including PD-1 (programmed death-1) and HER2 (human epidermal growth factor receptor-2). Its PD-1 geptanolimab has been prioritized to enter market evaluation.
Besides, the company plans to apply for New Drug Approval (NDA) for its two other medicine products.